Table 3.
Univariate | Multivariate | |||
---|---|---|---|---|
Factors | IFI (n=20) | No IFI (n= 362) | P-value Odds ratio (95% Confidence interval) |
P-value Odds ratio (95% confidence interval) |
Age (years), median | 58.1 | 56.6 | 0.51 | |
MELD, median (mean) | 25 (26.1) | 25 (26.4) | 0.78 | |
Re-transplant | 5% (1/20) | 8% (28/362) | 1.0 0.63 (0.08–4.87) |
|
Candida colonization before or at time of transplant | 5% (1/20) | 7% (25/362) | 1.0 0.71 (0.09–5.52) |
|
Reoperationa | 25% (5/20) | 22% (81/362) | 0.78 1.16 (0.41–3.28) |
|
Renal failure prior to transplant | 15% (3/20) | 16% (59/362) | 1.0 0.91 (0.26–3.19) |
|
Renal replacement therapy post- transplanta | 25% (5/20) | 27% (96/362) | 1.0 0.92 (0.33–2.61) |
|
Fulminant hepatic failure | 5% (1/20) | 2% (8/362) | 0.39 2.33 (0.28–19.60) |
|
Living donor | 35% (7/20) | 12% (42/362) | 0.008 4.10 (1.55–10.86) |
0.04 2.96 (1.05–8.40) |
Choledochojejunostomy | 20% (4/20) | 10% (36/362) | 0.15 2.26 (0.72–7.14) |
|
Operation length >11 hours | 25% (5/20) | 16% (58/362) | 0.35 1.75 (0.61–5.00) |
|
Intra-operative use of >40 units blood products | 0% (0/20) | 12% (42/362) | 0.15 0.18 (0.01–3.10) |
|
Operation length >11 hours AND intra-operative use of >40 Units blood products | 0% (0/20) | 5% (17/362) | 1.0 0.48 (0.03–8.30) |
|
Targeted antifungal prophylaxis | 50% (10/20) | 37% (135/362) | 0.34 1.68 (0.68–4.14) |
|
Bile leaks within 30 days post-transplant | 30% (6/20) | 4% (16/362) | 0.0004 9.27 (3.15–27.29) |
0.001 7.13 (2.31–22.04) |
Note: Bile leak within 30 days post-transplant and living donor remained independent risk factors for IFI when the types of antifungal prophylaxis was forced in the multivariate analysis model.
Total numbers of patients who required reoperation or renal replacement therapy post-transplant are lower than in Table 1 because only factors antecedent to the IFI are included
MELD= Model for End-Stage Liver Disease